Hemostemix talks social media, IR programs

Executive Summary

• Hemostemix Inc. announced updates to its investor awareness and social media strategies, including new opt-in SMS and email channels for investor communications.
• The company reported selling $1,143,983 in therapy convertible debentures year-to-date and highlighted significant clinical and commercial milestones for its VesCell therapy.
• CEO Thomas Smeenk emphasized the validation of patient testimonials through peer-reviewed data, citing specific Phase II results for chronic limb-threatening ischemia (CLTI) and dilated cardiomyopathy, while noting upcoming meetings with cardiologists in Florida.

Key Details

• Financing Update: The company reported forward sales of $1,143,983 in therapy convertible debentures year-to-date.
• Clinical Results (Dilated Cardiomyopathy): Cited Schubart et al. (Stem Cell Research and Therapy) showing cardiac improvements of up to a 47.1% increase in left ventricular ejection fraction (LVEF) in dilated cardiomyopathy patients after one treatment.
• Clinical Results (CLTI): Cited Henderson et al. (JBRES1876) regarding Phase II CLTI results, noting a 99% reduction in ulcerating wound size, decreasing from a mean of 146 square millimeters to 0.48 square millimeters by the end of month 3 (p=0.01).
• Long-term Mortality Data: Referenced a report by the University of British Columbia and University of Toronto to the 41st meeting of vascular surgeons, stating a 0% mortality rate for CLTI patients followed for up to 4.5 years, compared to a 50% five-year mortality rate in the general CLTI population.
• Clinical Milestones: The company has completed seven clinical studies involving 318 subjects and published results in 11 peer-reviewed publications.
• Awards: Mentioned the 2007 Frost and Sullivan Biotechnology Company of the Year Award (Asia) for VesCell achievements and the World Economic Forum Technology Pioneer Award.
• Investor Communication Channels:
  • Opt-in SMS alerts: Text 905-580-4170.
  • Opt-in email updates: [email protected].
  • Social media presence on Instagram, Facebook, LinkedIn, X (via @HeartRepairGuy), and YouTube for patient testimonials and corporate updates.
• Strategic Focus: The campaign aims to bridge patient recruitment (for no-option CLTI, PAD, and heart patients) with investor liquidity by highlighting the "asymmetrical investment upside" based on scientific validation.

Notable Quotes

• "Hemostemix has sold forward $1,143,983 in therapy convertible debenture year to date... Now, with 498 treatments, 11 peer-reviewed publications, including seven clinical studies of 318 subjects, including phase II results that validate our patients' testimonials, we are ramping up sales in Florida, investor outreach and patient engagement simultaneously." — Thomas Smeenk, CEO
• "Next week, I'm down to Florida to meet with cardiologists who have done their homework -- stay tuned." — Thomas Smeenk, CEO